NEOG shares gave up as much as 7.22% on FDA action over the recalled HYCOAT equine product. The selloff came with no earnings report on the calendar until October 6.

NEW YORK, Oct. 1, 2026 /PRNewswire/ — Wiping out as much as 7.22% of its value, Neogen Corporation (NASDAQ: NEOG) stock sold off after the FDA took warning action concerning HYCOAT, a recalled Neogen Vet product for horses. If you bought NEOG shares and are now holding losses, you are encouraged to submit your NEOG loss information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com  or by telephone at (888) SueWallSt.

No earnings report drove this move. Neogen’s next quarterly report is scheduled for October 6, and no guidance change or consensus miss accompanied the decline. The Chronicle-Journal, TradingView, Seeking Alpha, TipRanks, and Benzinga each reported the selloff.

The trigger was the product itself. FDA testing reportedly identified multiple fungal species in HYCOAT, which was marketed as sterile. Coverage linked the product to nearly 100 affected horses and at least 20 horse deaths. None of the reporting quantified potential fines, litigation costs, or reserve impacts for Neogen. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of NEOG investors who suffered losses.

If NEOG’s intraday selloff cut into your portfolio, have your NEOG losses reviewed today  or call Joseph E. Levi, Esq. at (888) SueWallSt.

WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the NEOG Investigation

Q: How much did NEOG stock drop?  A: Shares fell approximately 7.22%, following FDA warning action concerning the recalled Neogen Vet product HYCOAT, which reporting linked to fungal contamination, nearly 100 affected horses, and at least 20 horse deaths. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?  A: The investigation concerns whether Neogen may have made materially false or misleading statements regarding product quality and its Animal Safety segment, including the Neogen Vet product line. When FDA action concerning the recalled HYCOAT product became public, the stock fell over 7%.

Q: When did Neogen allegedly mislead investors?  A: The investigation concerns statements made before the FDA action concerning HYCOAT became public that allegedly caused investors to purchase securities at inflated prices.

Q: What do NEOG investors need to do right now?  A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?  A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my NEOG shares — can I still recover losses?  A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NEOG and sold at a loss may still participate in the investigation.

Q: Do I need to go to court or give testimony?  A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

Q: What does it cost me to participate?  A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@SueWallSt.com 

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neog-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-neogen-302895616.html

SOURCE SueWallSt.com